Alector, Inc.

NASDAQ:ALEC

Biotechnology

Healthcare
$2.57 +5.13%

+$0.08 today

Market cap
$382.61M
Beta
0.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.13
52W Low $1.09High $3.40

Volume 2.13M

Average 0.65M

ALEC Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Alector, Inc.NASDAQ: ALEC

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income dips below year-ago levels

Q1 FY2026 net income of $22.93M (cash outflow) fell 43.3% year over year, behind the +1.6% change in trailing-twelve-month net income. Sequentially, it fell 38.5% from the prior quarter. Over 3 fiscal years it compounded at +2.3% a year.

Context

  • Net income amounted to 679.2% of revenue in FY2025, up 560.8 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of $104.52M (+173.1%) for the fiscal year ending Dec 2026, a step up from the +20.1% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$22.93M-38.5% QoQ
Last fiscal yearDec 2025
-$142.93M+20.1% YoY
LTMMar 2026
-$125.39M+1.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-43.3%-15.8%+27.6 pp
1 year+20.1%+173.1%+153.1 pp
3-year CAGR+2.3%-22.4%-24.7 pp
5-year CAGR-14.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(142.93M) USD
Year-over-year change
-20.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ALEC compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1.6% is the 5th highest of 9, against a peer median of +2.6%.
  • Net income amounts to 680.8% of revenue for ALEC, versus a peer median of 1474.6%.
ALEC Competitors
Net Income for ALEC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VORVor Biopharma Inc.LTM Mar 2026$883.08M USD+644.6%+96.2%—
FATEFate Therapeutics, Inc.LTM Mar 2026$129.91M USD-26.1%-21.5%2056.8%
ALECAlector, Inc.LTM Mar 2026$125.39M USD+1.6%+2.3%680.8%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$113.28M USD-2.6%+41.5%—
IRDOpus Genetics, Inc.LTM Mar 2026$106.93M USD+82.4%—892.4%
NKTXNkarta, Inc.LTM Mar 2026$99.93M USD-10.2%-2.9%—
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$84.53M USD+68.1%+22.9%—
PEPGPepGen Inc.LTM Mar 2026$77.22M USD-24.4%+9.1%—
MOLNMolecular Partners AGLTM Mar 2026CHF 64.16M CHF+7.8%——
Peer median (excluding ALEC) —+2.6%+16.0%1474.6%

Competitors are the stored peer set for ALEC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(36.33M)(133.31M)(130.39M)(119.05M)(142.93M)
Depreciation & Amortization8.32M8.47M8.85M8.84M(861K)
Deferred Income Tax00000
Stock-Based Compensation40.79M46.15M42.8M39.46M26.66M
Change in Working Capital283.68M59.53M(90.15M)(146.99M)(74.06M)
Accounts Receivables(7.39M)4.8M2.59M00
Inventory00000
Accounts Payables1.92M(572K)(377K)(1.44M)(524K)
Other Working Capital289.16M55.29M(92.36M)(145.55M)(73.53M)
Other Non-Cash Items2.1M(1.16M)(15.27M)(12.17M)7.16M
Operating Cash Flow298.55M(20.33M)(184.16M)(229.91M)(184.03M)
Capital Expenditures(3.25M)(4.12M)(2.38M)(1.26M)(41K)
Acquisitions (Net)00000
Purchases of Investments(343.4M)(556.9M)(551.73M)(467.74M)(271.88M)
Sales of Investments296.99M402M656.03M576.13M468.52M
Other Investing Activities00000
Investing Cash Flow(49.66M)(159.01M)101.92M107.13M196.6M
Debt Repayment0009.39M0
Common Stock Issued04.51M2.55M71.11M20M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities30.3M001.04M217K
Financing Cash Flow30.3M4.51M2.55M81.54M20.22M
Effect of Forex Changes00000
Net Change in Cash279.18M(174.83M)(79.69M)(41.23M)32.78M
Free Cash Flow295.3M(24.45M)(186.54M)(231.16M)(184.07M)

Alector, Inc.

NASDAQ:ALEC

Intrinsic Alpha fair value

Locked

Current Price

$2.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.